Triple
T5872846
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | European Union pharmaceutical legislation |
E130557
|
entity |
| Predicate | monitoredBy |
P752
|
FINISHED |
| Object | Pharmacovigilance Risk Assessment Committee of the European Medicines Agency |
E130558
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Pharmacovigilance Risk Assessment Committee of the European Medicines Agency | Statement: [European Union pharmaceutical legislation, monitoredBy, Pharmacovigilance Risk Assessment Committee of the European Medicines Agency]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Pharmacovigilance Risk Assessment Committee of the European Medicines Agency Context triple: [European Union pharmaceutical legislation, monitoredBy, Pharmacovigilance Risk Assessment Committee of the European Medicines Agency]
-
A.
Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
-
B.
Pharmacovigilance Risk Assessment Committee
chosen
The Pharmacovigilance Risk Assessment Committee is a scientific body responsible for evaluating and monitoring the safety of human medicines and advising on risk management measures in the European Union.
-
C.
Committee for Medicinal Products for Human Use
The Committee for Medicinal Products for Human Use is the European Medicines Agency’s expert body responsible for evaluating and providing scientific opinions on the safety, quality, and efficacy of medicines for human use in the European Union.
-
D.
WHO Collaborating Centre for Drug Statistics Methodology
The WHO Collaborating Centre for Drug Statistics Methodology is a specialized World Health Organization center responsible for developing and maintaining international standards for drug classification and consumption statistics, including the ATC/DDD system.
-
E.
Conditional Marketing Authorization by European Medicines Agency
Conditional Marketing Authorization by the European Medicines Agency is a fast-track regulatory pathway that allows earlier approval of medicines, such as COVID-19 vaccines, based on less comprehensive data than normally required, provided that the benefits outweigh the risks and additional data will be supplied post-approval.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69c0085047dc8190af24e311edad3c07 |
completed | March 22, 2026, 3:18 p.m. |
| NER | Named-entity recognition | batch_69c035f99b788190b5b06d83b9499bfa |
completed | March 22, 2026, 6:33 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69c0b11b48d88190ba6cd5ade2f47a89 |
completed | March 23, 2026, 3:18 a.m. |
Created at: March 22, 2026, 3:56 p.m.